Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) Updates On Clinical Trial of RX-3117

0
1389

Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) reported an interim update on the efficacy and safety of RX-3117 in an upcoming Phase IIa clinical study in metastatic bladder cancer at the ASCO 2017 Annual Meeting.

The details

Ely Benaim, M.D., the Chief Medical Officer of Rexahn, reported that the trial achieved predefined standard for efficacy in metastatic bladder cancer. 20% of subjects demonstrated progression free survival of over six months and tumor reduction was noted in some patients. It is not anticipated in people with metastatic bladder cancer who have failed three or more previous cancer therapies and have advanced resistance to many of anticancer agents.

Current alternatives for these subjects are usually limited to best supportive or palliative care. So, the company is extremely delighted with the outcome in this initial stage of the trial and they will continue to register additional patients into the next phase of this Phase 2a study.

People suffering with metastatic bladder cancer and also who have advanced resistance to gemcitabine treatments, are extremely tough to treat. It was extremely unexpected to witness prolonged stable disease in people in this trial who had failed numerous prior treatments that comprised cisplatin/ gemcitabine and immunotherapy, so this initial report is extremely encouraging. RX-3117 seems to be remarkably well-tolerated and safe with no visible dose limiting side-effects.

Rexahn presented the updated efficacy report for RX-3117 from an underway Phase 2a clinical study in metastatic bladder cancer earlier this month in a poster presentation. The poster presentation announced data on the preliminary ten patients registered into stage I of a two stage Phase 2a trial in metastatic bladder cancer. Subjects registered into stage I of the clinical study had progressing bladder cancer with distinct metastases to numerous sites counting the liver, lymph nodes, pelvis and lung. In stage I of the current trial, two of ten patients cured with RX-3117 showed progression free survival of over 6 months.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.